Literature DB >> 22194476

Multicontrast single-slab 3D MRI to detect cerebral metastasis.

Weiwei Chen1, Liang Wang, Wenzhen Zhu, Liming Xia, Jianpin Qi, Dingyi Feng, Xin Luo.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the sensitivities and specificities of four single-slab 3D MRI sequences in the detection of cranial metastases: double inversion recovery (IR), T2 FLAIR, contrast-enhanced T2 FLAIR, and contrast-enhanced IR-prepared fast spoiled gradient-echo (FSPGR) sequences. SUBJECTS AND METHODS: Eighty-four patients underwent double IR and T2 FLAIR imaging using 3-T MRI. Then, 49 of 84 patients were randomly selected to undergo contrast-enhanced IR-prepared FSPGR before contrast-enhanced T2 FLAIR, and the other 35 patients underwent contrast-enhanced T2 FLAIR before contrast-enhanced IR-prepared FSPGR. Two experienced neuroradiologists reviewed the images by consensus on a workstation. Metastases were scored a negative, equivocal, or positive. For each metastasis, we recorded the anatomic area and size, and checked whether edema was present.
RESULTS: A total of 210 cranial metastases in 56 of 84 patients were revealed. The sensitivities of double IR, T2 FLAIR, contrast-enhanced IR-prepared FSPGR, and contrast-enhanced T2 FLAIR sequences were 66.2%, 56.7%, 80.5%, and 99%, respectively. The specificities were 68.3%, 73%, 75.7%, and 82.4%. The areas under the receiver operating characteristic curve were 0.763, 0.709, 0.865, and 0.993. Contrast-enhanced T2 FLAIR imaging was found to have the highest sensitivity especially for detecting lesions in meninges (98.2%; p<0.0001) and gray matter (GM) (100%; p<0.0001). The double IR sequence was superior to the T2 FLAIR sequence for imaging metastases located in ependyma (81.8% vs 36.4%) and GM (66.7% vs 48.1%). Delayed enhancement did not affect the sensitivities of the contrast-enhanced T2 FLAIR and contrast-enhanced IR-prepared FSPGR sequences.
CONCLUSION: Contrast-enhanced T2 FLAIR is the most sensitive sequence of the four MR sequences evaluated for the detection of cranial metastases despite its delay time after contrast enhancement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22194476     DOI: 10.2214/AJR.11.7030

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

Review 1.  The detectability of brain metastases using contrast-enhanced spin-echo or gradient-echo images: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Seung Chai Jung; Kyung Won Kim; Junhee Pyo
Journal:  J Neurooncol       Date:  2016-06-20       Impact factor: 4.130

2.  Comparison of contrast-enhanced T1-weighted imaging using DANTE-SPACE, PETRA, and MPRAGE: a clinical evaluation of brain tumors at 3 Tesla.

Authors:  Zi-Qiao Lei; Chuan-Sheng Zheng; Qing Fu; Qi-Guang Cheng; Xiang-Chuang Kong; Ding-Xi Liu; Yi-Hao Guo; John Grinstead; Xiao-Yong Zhang
Journal:  Quant Imaging Med Surg       Date:  2022-01

3.  Time-delayed contrast-enhanced MRI improves detection of brain metastases: a prospective validation of diagnostic yield.

Authors:  Or Cohen-Inbar; Zhiyuan Xu; Blair Dodson; Tanvir Rizvi; Christopher R Durst; Sugoto Mukherjee; Jason P Sheehan
Journal:  J Neurooncol       Date:  2016-08-27       Impact factor: 4.130

4.  A comparison of high b-value vs standard b-value diffusion-weighted magnetic resonance imaging at 3.0 T for medulloblastomas.

Authors:  Chengkun Han; Long Zhao; Shan Zhong; Xiurong Wu; Jianfeng Guo; Xiongjie Zhuang; Haiwei Han
Journal:  Br J Radiol       Date:  2015-08-03       Impact factor: 3.039

Review 5.  The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis.

Authors:  Rasheed Zakaria; Kumar Das; Maneesh Bhojak; Mark Radon; Carol Walker; Michael D Jenkinson
Journal:  Cancer Imaging       Date:  2014-04-22       Impact factor: 3.909

6.  Sensitivity of different MRI sequences in the early detection of melanoma brain metastases.

Authors:  Katerina Deike-Hofmann; Daniel Thünemann; Michael O Breckwoldt; Daniel Schwarz; Alexander Radbruch; Alexander Enk; Martin Bendszus; Jessica Hassel; Heinz-Peter Schlemmer; Philipp Bäumer
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.